CJC-1295 vs Ipamorelin: Differences, Stacking & Safety | telos rx
Sprinter crouched at the starting line on a red track, illustrating CJC-1295 vs ipamorelin and growth hormone peptides for performance
← Back to blog
CJC-1295

CJC-1295 vs Ipamorelin: Key Differences Compared

By TelosRX Editorial Team Updated

CJC-1295 vs ipamorelin comes down to receptors. CJC-1295 mimics GHRH to extend the growth hormone signal, while ipamorelin hits the ghrelin receptor to trigger a short, selective pulse. Neither is FDA-approved. TelosRX explains how providers evaluate the pairing.

Search for growth hormone peptides and these two names show up together almost every time. That's not an accident. They're usually sold, studied, and discussed as a pair.

But they're not the same thing. They act on different receptors, last different lengths of time, and carry different research histories. If you want to understand why people stack them, you first need to know how each one works on its own.

CJC-1295 vs Ipamorelin at a Glance

Here's the head-to-head summary. Every row is unpacked in the sections below.

Feature CJC-1295 Ipamorelin
Drug class GHRH analog (lab-made version of growth hormone-releasing hormone) Growth hormone secretagogue (a compound that prompts GH release)
Receptor GHRH receptor on the pituitary Ghrelin receptor (GHS-R1a) on the pituitary
Main job Primes and extends the GH signal Triggers a discrete GH pulse
Half-life About 30 minutes without DAC; roughly 6 to 8 days with DAC About 2 hours
Dosing pattern in studies or reported protocols Weekly or less often (with DAC); daily (without DAC) Once to several times daily
Cortisol and prolactin Minimal effect reported No meaningful rise in early selectivity studies
Appetite No notable effect Little effect, unlike older ghrelin mimics
Human evidence Small pharmacology studies in healthy adults Early-phase human trials; never approved
FDA status Not FDA-approved Not FDA-approved
Sport testing Prohibited by WADA Prohibited by WADA

The short version: CJC-1295 sets the stage, and ipamorelin pulls the trigger. That's why they're paired so often.

What Is CJC-1295?

CJC-1295 is a lab-made peptide based on the first 29 amino acids of GHRH. That's the hormone your hypothalamus releases to tell your pituitary to make growth hormone.

Natural GHRH breaks down within minutes. CJC-1295 has four amino acid swaps that make it harder for enzymes to chew up. The result is a longer-lasting version of the same signal.

It binds the GHRH receptor and activates the cAMP pathway (a chemical relay inside the cell). That drives both GH production and release.

CJC-1295 With DAC vs Without DAC

This is where most confusion starts. "CJC-1295" can mean two different compounds.

  • CJC-1295 with DAC. DAC stands for Drug Affinity Complex. It lets the peptide latch onto albumin, a blood protein. That stretches its half-life to days.
  • CJC-1295 without DAC. Also called Mod GRF 1-29. Same stabilizing swaps, no albumin hook. It clears in about 30 minutes.

The DAC version produces a long, steady rise in GH signaling. The no-DAC version gives a brief boost that sits closer to your body's natural rhythm. Most pairings with ipamorelin use the no-DAC form for that reason.

When you see a product or protocol, always check which version it is. They behave very differently.

What Is Ipamorelin?

Ipamorelin is a five-amino-acid peptide first described by Novo Nordisk researchers in the late 1990s. It belongs to the growth hormone releasing peptide (GHRP) family.

It works on the ghrelin receptor. Ghrelin is best known as the "hunger hormone," but its receptor on the pituitary also triggers GH release.

What made ipamorelin stand out was selectivity. In the original 1998 characterization study, it released GH without raising ACTH or cortisol beyond levels seen with GHRH. That held even at doses far above what GH release required. Older GHRPs like GHRP-6 raised cortisol, prolactin, and hunger along with GH.

How Their Mechanisms Differ

Both peptides end up at the same place: GH-producing cells in the pituitary. They just knock on different doors.

  • CJC-1295 uses the GHRH receptor and the cAMP relay. Think of it as loading the cell with GH and getting it ready.
  • Ipamorelin uses the ghrelin receptor and a calcium-based relay. Think of it as the signal to release what's ready.

Ghrelin-receptor agonists also appear to dampen somatostatin, the body's "stop GH" signal. That gives the GHRH signal less resistance.

Because the two pathways are independent, they don't compete. That's the scientific basis for pairing them.

Half-Life and Dosing Frequency Compared

Half-life (how long until half the drug is gone) drives how often each peptide is dosed.

Compound Approximate half-life Typical frequency
CJC-1295 with DAC About 6 to 8 days Once weekly or less often in studies
CJC-1295 without DAC About 30 minutes Once or twice daily in reported protocols
Ipamorelin About 2 hours Once to several times daily in reported protocols

In a 2006 study in healthy adults, a single CJC-1295 (with DAC) injection raised average GH levels two- to tenfold for six days or more. IGF-1, the main downstream marker of GH activity, rose 1.5- to threefold for 9 to 11 days.

Reported protocols often time doses at bedtime on an empty stomach. Food, especially carbs, can blunt GH release. Specific dosing is a provider decision. Nothing here is a dosing recommendation.

Want a deeper look at timing? Our ipamorelin half-life Q&A covers it in detail.

Growth Hormone Pulse Patterns

Your body releases GH in bursts, with the biggest ones during deep sleep. A natural pattern matters because tissues respond to pulses, not just averages.

A follow-up 2006 study found that GH kept its pulsing pattern even during continuous stimulation by CJC-1295 with DAC. The peaks rose, but the rhythm stayed.

Ipamorelin produces a sharp, short pulse each time it's given. Paired with no-DAC CJC-1295, the goal in reported protocols is a bigger version of a natural burst rather than a flat, constant rise.

Side Effects: How They Compare

Neither peptide has long-term human safety data. The side effects below come from short studies and clinical reports.

Effect CJC-1295 Ipamorelin
Injection site redness or irritation Common Common
Flushing after injection Reported, especially with DAC Less often reported
Headache Reported Reported
Water retention or tingling Reported at higher exposure Occasionally reported
Nausea or lightheadedness Occasionally reported Occasionally reported, usually early
Cortisol or prolactin rise Not typical Not seen in early selectivity research

Any compound that raises GH and IGF-1 also carries broader cautions. Higher IGF-1 can affect blood sugar and insulin sensitivity. That's why lab monitoring matters.

What the Research Actually Shows

This is the honest part. The human evidence is thin for both.

  • CJC-1295: Small pharmacology studies show it raises GH and IGF-1 in healthy adults. Those studies measured hormone levels, not body composition, strength, or aging outcomes. Clinical development was stopped years ago.
  • Ipamorelin: Animal and early human studies confirm selective GH release. It reached mid-stage human testing for post-surgical gut slowdown, but it was never approved for any use.
  • The stack: No controlled trial has tested CJC-1295 plus ipamorelin together for muscle, fat loss, sleep, or longevity. The case for pairing rests on mechanism and older GHRH-plus-GHRP synergy research.

So when you see claims about dramatic results, read them as anecdotes, not evidence. Studies suggest hormone changes. They don't yet show proven real-world outcomes.

Why CJC-1295 and Ipamorelin Are Often Stacked

Decades-old research found that GHRH plus a GHRP releases more GH than either alone. The combined effect was larger than the sum of the parts.

That synergy is the reason these two are usually paired. CJC-1295 primes the cells. Ipamorelin triggers release. And ipamorelin's selectivity keeps the cortisol and appetite side effects of older GHRPs out of the picture.

Curious how TelosRX approaches this pairing? See the CJC-1295 / Ipamorelin page at TelosRX. Any prescription is subject to medical approval by a licensed provider, and approval isn't guaranteed.

How They Compare to Sermorelin and Tesamorelin

CJC-1295 isn't the only GHRH analog. Two others come up often.

Compound Class Half-life Regulatory history
Sermorelin GHRH analog (GHRH 1-29) Minutes Once FDA-approved as Geref for pediatric GH deficiency; brand discontinued by its maker
Tesamorelin Stabilized GHRH analog About 26 to 38 minutes FDA-approved (Egrifta) to reduce excess abdominal fat in adults with HIV-associated lipodystrophy
CJC-1295 Modified GHRH analog 30 minutes to about 8 days Not FDA-approved

Sermorelin is the shortest-acting of the group and has the longest clinical history. Compare the two in our sermorelin vs CJC-1295 breakdown, or see ipamorelin vs sermorelin for the cross-class view.

If an oral option interests you, our MK-677 vs ipamorelin comparison covers the pill-form secretagogue.

Lab Monitoring on Growth Hormone Peptides

Because these peptides push the GH axis, providers typically want numbers before and during use. Common checks include:

  • IGF-1. The most practical marker of GH activity. Levels well above the age range usually prompt a dose review.
  • Fasting glucose and A1c. GH can nudge blood sugar up.
  • Metabolic panel. A baseline view of kidney and liver function.
  • Thyroid panel. Thyroid issues can mimic or mask GH-related symptoms.

Your provider decides which labs fit your history. Labs are part of safe use, not an optional extra.

Regulatory Status and Sport Testing

Neither CJC-1295 nor ipamorelin is FDA-approved for any human use. Both are compounds that are not approved as finished drugs, and their status for pharmacy compounding has shifted during ongoing FDA review.

That means availability depends on current federal compounding rules and a provider-issued prescription. Products sold online as "research chemicals" are not the same thing. They're labeled not for human use and aren't made under pharmacy standards.

For athletes: both are on the World Anti-Doping Agency's prohibited list. If you compete in a tested sport, they're off the table.

Who Should Avoid Growth Hormone Peptides

These peptides aren't a fit for everyone. Providers are generally cautious or decline in these situations:

  • Active cancer, or a recent cancer history
  • Uncontrolled diabetes or significant insulin resistance
  • Pregnancy or breastfeeding
  • Serious heart disease that needs active management
  • Competitive athletes subject to drug testing

Your full medical history shapes the answer. That's why an honest intake matters.

Which to Consider: Questions to Ask Your Provider

There's no universal winner here. CJC-1295 and ipamorelin do different jobs, and most protocols use them together. Instead of picking a "best" peptide, bring these questions to your provider:

  1. What's my goal? Sleep, recovery, and body composition are common reasons people ask. Be specific.
  2. Which CJC-1295 version is this? DAC and no-DAC behave very differently.
  3. Do I need the pair, or one alone? Ipamorelin alone gives a simpler, short pulse.
  4. Is a GHRH analog with more history a better fit? Sermorelin may come up.
  5. What labs will we track? IGF-1 and glucose at minimum.
  6. What's the plan if side effects show up? Know the stop rules before you start.

Lifestyle still does the heavy lifting. Deep sleep, resistance training, and enough protein all support your natural GH rhythm, no injection required.

How TelosRX Handles Peptide Requests

TelosRX is an asynchronous telehealth service. You complete a secure online intake whenever it suits you. A licensed provider reviews your history, goals, and any labs.

If a peptide is appropriate and permitted under current rules, the provider may issue a prescription. If it isn't, they'll tell you why. You can message your care team any time, with no live appointment required.

Want to explore a GHRH option with a longer track record? Visit our sermorelin page.

Frequently Asked Questions

Is CJC-1295 or ipamorelin better?

Neither is better in general, because they do different jobs. CJC-1295 is a GHRH analog that primes and extends the growth hormone signal. Ipamorelin is a ghrelin-receptor agonist that triggers a short, selective pulse. That's why they're usually paired. The right choice depends on your goals, history, and labs, and it's a decision for a licensed provider.

Can you take CJC-1295 and ipamorelin together?

They're commonly combined because they act on separate pituitary receptors. Older research on GHRH and GHRP pairings found more growth hormone release together than with either alone. No controlled trial has tested this specific pair for real-world outcomes, though. Any combined protocol should come from a provider-issued prescription with lab monitoring, never from research-chemical sellers.

What is the difference between CJC-1295 with DAC and without DAC?

DAC lets CJC-1295 bind to albumin in the blood, stretching its half-life from about 30 minutes to roughly six to eight days. The DAC version gives a long, steady rise in growth hormone signaling with infrequent dosing. The no-DAC version, also called Mod GRF 1-29, gives a brief boost closer to the body's natural pulse pattern.

Does ipamorelin raise cortisol or hunger?

Early selectivity research found ipamorelin released growth hormone without a meaningful rise in ACTH or cortisol, even at high doses. It also showed little appetite effect, unlike older peptides such as GHRP-6. Those findings come from animal and early human studies. Individual responses can still vary, so report any new symptoms to your provider.

Are CJC-1295 and ipamorelin FDA-approved?

No. Neither peptide is FDA-approved for any human use. Their status for pharmacy compounding has changed during ongoing FDA review, so access depends on current federal rules and a licensed provider's judgment. Products sold online as research chemicals are labeled not for human use and aren't made under pharmacy standards.

Are CJC-1295 and ipamorelin banned in sports?

Yes. Both appear on the World Anti-Doping Agency's prohibited list. CJC-1295 falls under growth hormone-releasing factors, and ipamorelin falls under growth hormone secretagogues. If you compete in a tested sport, using either one can lead to sanctions. Check your sport's rules and talk to your provider before considering any growth hormone peptide.

TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.

Start your private evaluation at TelosRX.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX